An sake buga wannan labarin daga fitowar ta 97 na “Ganoderma” a cikin 2023, wanda aka buga tare da izinin marubuci.Duk haƙƙoƙin wannan labarin nasa ne na marubucin.

Ana iya lura da babban bambanci a cikin kwakwalwa tsakanin mutum mai lafiya (hagu) da mai cutar Alzheimer (dama).

(Madogaran Hoto: Wikimedia Commons)

Ciwon Alzheimer (AD), wanda aka fi sani da lalatawar tsofaffi, cuta ce mai ci gaba ta neurodegenerative cuta wacce ke da alaƙar fahimi da ke da alaƙa da asarar ƙwaƙwalwa.Tare da haɓakar rayuwar ɗan adam da tsufa na yawan jama'a, yawan cutar Alzheimer yana ƙaruwa akai-akai, yana haifar da nauyi mai yawa akan iyalai da al'umma.Saboda haka, binciko hanyoyin da yawa don rigakafi da magance cutar Alzheimer ya zama batun babban sha'awar bincike.

A cikin labarina mai suna "Bincike Bincike akanGanodermadon Rigakafi da Magance Cutar Alzheimer,” wanda aka buga a cikin fitowar ta 83 na mujallar “Ganoderma” a cikin 2019, Na gabatar da cututtukan cututtukan Alzheimer da tasirin magunguna naGanodermalucidumwajen yin rigakafi da magance cutar Alzheimer.Musamman,Ganodermalucidumtsantsa,Ganodermalucidumpolysaccharides,Ganodermalucidumtriterpenes, kumaGanodermalucidumspore foda an samo su don inganta ilmantarwa da ƙwaƙwalwar ajiya a cikin nau'in bera na cutar Alzheimer.Wadannan sassan kuma sun nuna tasirin kariya daga canje-canjen neuropathological na degenerative a cikin kwakwalwar kwakwalwar hippocampal na nau'in bera na cutar Alzheimer, rage yawan kumburi a cikin kyallen takarda, ƙara yawan aikin superoxide dismutase (SOD) a cikin kwakwalwar kwakwalwar hippocampal, rage matakan malondialdehyde (MDA). ) a matsayin samfurin oxidative, kuma ya nuna rigakafi da tasirin warkewa a cikin samfuran dabbobi na gwaji na cutar Alzheimer.

Biyu na farko binciken asibiti a kanGanoderma lucidumdon hanawa da magance cutar Alzheimer, wanda aka gabatar a cikin labarin, ba a tabbatar da ingancin ingancin baGanoderma luciduma cikin cutar Alzheimer.Koyaya, haɗe tare da ɗimbin binciken bincike na ilimin harhada magunguna, suna ba da bege don ƙarin karatun asibiti.

Tasirin amfaniGanoderma lucidumspore foda kadai don magance cutar Alzheimer ba a bayyane yake ba.

Yin bitar takardar bincike mai suna "Spore foda naGanoderma lucidumdon maganin cutar Alzheimer: Nazarin matukin jirgi" da aka buga a cikin mujallar "Medicine"^[1], Mawallafa sun raba marasa lafiya 42 da bazuwar wadanda suka hadu da ka'idojin bincike don cutar Alzheimer a cikin ƙungiyar gwaji da ƙungiyar kulawa, tare da marasa lafiya 21 a cikin kowane rukuni.Ƙungiya ta gwaji ta karbi maganin baka naGanodermalucidumspore foda capsules (SPGL kungiyar) a wani sashi na 4 capsules (250 MG kowane capsule) sau uku a rana yayin da ƙungiyar kulawa kawai ta sami capsules placebo.Dukan kungiyoyin biyu sun yi jinya na mako 6.

A karshen jiyya, idan aka kwatanta da kungiyar ke sarrafawa, kungiyar SPGL ta nuna ragi a cikin sakamakon tantancewar cutar Alzheimer (NPI), wanda ke nuna cigaba da hankali da halaye nakasu, amma bambance-bambancen ba su da mahimmanci a kididdiga (Table 1).Tambayoyi na Hukumar Lafiya ta Duniya na Ingancin Rayuwa-BREF (WHOQOL-BREF) ya nuna karuwar ƙimar ingancin rayuwa, yana nuna haɓakar ingancin rayuwa, amma kuma, bambance-bambancen ba su da mahimmanci a ƙididdiga (Table 2).Dukansu ƙungiyoyin sun sami raɗaɗi mara kyau, ba tare da bambance-bambance ba.

Mawallafin takarda sun yi imanin cewa maganin cutar Alzheimer tare daGanoderma lucidumspore foda capsules na makonni 6 bai nuna tasiri mai mahimmanci na warkewa ba, mai yiwuwa saboda ɗan gajeren lokaci na jiyya.Ana buƙatar gwaje-gwaje na asibiti na gaba tare da manyan samfurori masu girma da kuma tsawon lokaci na magani don samun ƙarin fahimtar ingancin asibiti.Ganoderma lucidumspore foda capsules a cikin maganin cutar Alzheimer.

A hade amfani daGanoderma lucidumspore foda tare da magungunan jiyya na al'ada yana inganta ingantaccen maganin warkewa a cikin zalunta cutar Alzheimer.

Kwanan nan, wani bincike ya kimanta tasirin haɗin gwiwarGanoderma lucidumspore foda da kuma memantine na cutar Alzheimer a kan cognition da ingancin rayuwa a cikin marasa lafiya tare da cutar Alzheimer mai sauƙi zuwa matsakaici [2].Marasa lafiya arba'in da takwas da aka gano tare da cutar Alzheimer, masu shekaru 50 zuwa 86 shekaru, an raba su cikin bazuwar zuwa ƙungiyar kulawa da ƙungiyar gwaji, tare da marasa lafiya 24 a kowace ƙungiya (n=24).

Kafin jiyya, babu wani bambance-bambance mai mahimmanci tsakanin ƙungiyoyi biyu dangane da jinsi, digiri na dementia, ADAS-cog, NPI, da WHOQOL-BREF (P> 0.5).Ƙungiyar kulawa ta karbi magungunan memantine a kashi na 10 MG, sau biyu a rana, yayin da ƙungiyar gwaji ta sami kashi ɗaya na memantine tare da.Ganoderma lucidumspore foda capsules (SPGL) a kashi na 1000 MG, sau uku a rana.An bi da ƙungiyoyin biyu don makonni 6, kuma an rubuta ainihin bayanan marasa lafiya.An kimanta aikin fahimi da ingancin rayuwar marasa lafiya ta amfani da ma'aunin ma'auni na ADAS-cog, NPI, da WHOQOL-BREF.

Bayan jiyya, duka ƙungiyoyin marasa lafiya sun nuna raguwa mai yawa a cikin ADAS-cog da maki NPI idan aka kwatanta da kafin magani.Bugu da ƙari, ƙungiyar gwaji ta sami ƙananan ƙimar ADAS-cog da NPI fiye da ƙungiyar kulawa, tare da bambance-bambance masu mahimmanci (P<0.05) (Table 3, Table 4).Bayan jiyya, duka ƙungiyoyin marasa lafiya sun nuna karuwa mai yawa a cikin ƙididdiga don ilimin lissafi, ilimin halin dan Adam, dangantakar zamantakewa, yanayi, da kuma yanayin rayuwa gaba ɗaya a cikin tambayoyin WHOQOL-BREF idan aka kwatanta da kafin magani.Bugu da ƙari, ƙungiyar gwaji ta sami maki mafi girma na WHOQOL-BREF fiye da ƙungiyar kulawa, tare da bambance-bambance masu mahimmanci (P<0.05) (Table 5).

Memantine, wanda aka sani da labari N-methyl-D-aspartate (NMDA) antagonist mai karɓa, ba zai iya hana masu karɓar NMDA ba tare da gasa ba, ta haka yana rage glutamic acid-induced NMDA mai karɓar mai karɓa da kuma hana apoptosis cell.Yana inganta aikin fahimi, matsalar ɗabi'a, ayyukan rayuwar yau da kullun, da tsananin rashin ƙarfi a cikin marasa lafiya da cutar Alzheimer.Ana amfani da shi don maganin cutar Alzheimer mai laushi, matsakaici da mai tsanani.Duk da haka, amfani da wannan magani kadai har yanzu yana da iyakacin fa'ida ga marasa lafiya da cutar Alzheimer.

Sakamakon wannan binciken ya nuna cewa haɗakar aikace-aikacenGanoderma lucidumspore foda da memantine na iya haɓaka halayen halayen marasa lafiya da iyawar fahimta kuma suna inganta yanayin rayuwarsu.

Zaɓin hanyar magani mai kyau yana da mahimmanci don magance cutar Alzheimer.

A cikin sama biyu bazuwar sarrafawa gwaje-gwajen asibiti naGanoderma lucidumspore foda don maganin cutar Alzheimer, zaɓin lokuta, ganewar asali, tushen Ganoderma lucidum spore foda, sashi, hanya na jiyya, da ma'auni na ƙimar inganci sun kasance iri ɗaya, amma tasirin asibiti ya bambanta.Bayan ƙididdigar ƙididdiga, amfani daGanoderma lucidumspore foda kadai don magance cutar Alzheimer bai nuna wani gagarumin ci gaba a cikin AS-cog, NPI, da WHOQOL-BREF maki idan aka kwatanta da placebo;duk da haka, a hade amfani daGanoderma lucidumspore foda da memantine sun nuna gagarumin ci gaba a cikin maki uku idan aka kwatanta da memantine kadai, wato, hadewar amfani daGanoderma lucidumspore foda da memantine na iya inganta haɓaka halayyar hali, iyawar fahimta da ingancin rayuwar marasa lafiya tare da cutar Alzheimer.

A halin yanzu, magungunan da ake amfani da su don magance cutar Alzheimer, irin su donepezil, rivastigmine, memantine, da galantamine (Reminyl), suna da iyakacin tasirin warkewa kuma suna iya rage alamun bayyanar cututtuka kawai da jinkirta yanayin cutar.Bugu da kari, kusan ba a sami nasarar samar da wasu sabbin magunguna na maganin cutar Alzheimer cikin shekaru 20 da suka gabata ba.Saboda haka, yin amfani daGanoderma lucidumspore foda don haɓaka tasirin magunguna don maganin cutar Alzheimer ya kamata a ba da hankali.

Amma ga ƙarin gwaji na asibiti na amfaniGanoderma lucidumspore foda kadai, yana iya yiwuwa a yi la'akari da ƙara yawan adadin, misali, 2000 MG kowane lokaci, sau biyu a rana, don hanya na akalla 12 makonni.Ko wannan yana yiwuwa, muna sa ran samun sakamakon bincike a wannan yanki don gaya mana amsar.

[References]

1. Guo-hui Wang, et al.Spore foda naGanoderma lucidumdon maganin cutar Alzheimer: Nazarin matukin jirgi.Magunguna (Baltimore)2018;97(19): e0636.

2. Wang Lichao, et al.Tasirin memantine hade daGanoderma lucidumspore foda akan cognition da ingancin rayuwa a cikin marasa lafiya da cutar Alzheimer.Jaridar Kwalejin Kiwon Lafiyar 'Yan Sanda (Likitan Likita).2019, 28 (12): 18-21.

Gabatarwa ga Farfesa Lin Zhibin

Mr. Lin Zhibin, majagaba a cikiGanodermabincike a kasar Sin, ya sadaukar da kusan rabin karni ga fannin.Ya rike mukamai da dama a jami'ar kiwon lafiya ta Beijing, ciki har da mataimakin shugaban kasa, mataimakin shugaban makarantar koyon aikin likitanci, da darektan cibiyar nazarin kimiyyar likitanci, da daraktan sashen kula da harhada magunguna.Yanzu shi malami ne a Sashen Nazarin Magunguna a Makarantar Kiwon Lafiya ta Jami'ar Peking.Daga 1983 zuwa 1984, ya kasance malami mai ziyara a Cibiyar Nazarin Magungunan Gargajiya ta WHO a Jami'ar Illinois a Chicago.Daga 2000 zuwa 2002, ya kasance malami mai ziyara a Jami'ar Hong Kong.Tun 2006, ya kasance malami mai daraja a Cibiyar Magunguna ta Jihar Perm a Rasha.

Tun daga shekarar 1970, ya yi amfani da hanyoyin kimiyya na zamani don nazarin illolin harhada magunguna da hanyoyin maganin gargajiya na kasar Sin.Ganodermada kayan aikin sa.Ya buga fiye da ɗari takardun bincike a kan Ganoderma.Daga 2014 zuwa 2019, an zabe shi a cikin jerin masu bincike na Elsevier na kasar Sin da aka ambata sosai tsawon shekaru shida a jere.

Ya rubuta littattafai da yawa a kan Ganoderma, ciki har da "Bincike na zamani akan Ganoderma" (bugu na 1-4th), "Lingzhi daga Mystery zuwa Kimiyya" (1st-3rd edition), "Ganoderma yana goyan bayan makamashi mai lafiya kuma yana watsar da abubuwan pathogenic, yana taimakawa a cikin maganin ciwace-ciwacen daji", "Tattaunawa akan Ganoderma", da "Ganoderma da Lafiya".